Trial Data. Revealed.

Results of the ECI® osteosarcoma treatment were presented at the 2018 Veterinary Cancer Society with the researchers determining it to be safe and tolerable in the study. Median Survival Time for dogs completing the osteosarcoma protocol was 415 days. It was further noted that this median survival time exceeded those typically reported for those patients receiving amputation plus chemotherapy. The promise of improved disease survival outcomes and better quality of life for cancer patients is being revealed in the data.

ACVIM Video/Presentation

Autologous Activated T cell Therapy for Canine Osteosarcoma
Brian K Flesner, DVM, MS, DACVIM (Oncology), University of Missouri
Presented at ACVIM 2018, Seattle, WA

Intro, Diagnosis, Staging and Protocol

Possible Adverse Events

Efficacy, Outcomes and Case Studies

Key Insights, Acknowledgments and Summary

Real Cancer Patients. Helped.

While the data is promising, the effect on the lives of beloved dogs is truly inspiring. Families have also gained more time with their cherished companions who are enjoying a better quality of life. This is why we’re working so hard to advance cancer therapy in dogs.

See Roscoe in Action